Latest News for: her2 positive

Edit

Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early ...

The Galveston Daily News 16 May 2026
TOKYO--(BUSINESS WIRE)--May 15, 2026-- ....
Edit

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive ...

Caledonian Record 16 May 2026
WILMINGTON, Del.--(BUSINESS WIRE)--May 15, 2026-- ....
Edit

Enhertu� Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early ...

Business Wire 16 May 2026
TOKYO--(BUSINESS WIRE)--Enhertu Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer ... .
Edit

Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer (Daiichi Sankyo Co Ltd)

Public Technologies 16 May 2026
... Approximately one in three patients with HER2 positive early-stage breast cancer is considered high-risk, meaning they are more likely to experience disease recurrence and have a poor prognosis.5.
Edit

Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer (AstraZeneca plc)

Public Technologies 16 May 2026
With Enhertu, AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive, HER2-low and HER2-ultralow metastatic breast cancer, and expanding its potential in ...
Edit

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer (AstraZeneca Pharmaceuticals LP)

Public Technologies 16 May 2026
HER2-Positive, HER2-Low, and HER2-Ultralow Breast Cancer, HER2-Mutant NSCLC, and Solid Tumors (Including IHC 3+) (5.4 mg/kg) ... HER2-Positive, HER2-Low, and HER2-Ultralow Breast Cancer, HER2-Mutant NSCLC, and Solid Tumors (Including IHC 3+) (5.4 mg/kg).
Edit

PHERGain and PHERGain-2 advance therapeutic de-escalation in early HER2-positive breast cancer in selected patients

PR Newswire 07 May 2026
Both studies evaluate de-escalation strategies based on targeted therapies in HER2-positive early breast cancer, with the aim of identifying which patients could safely avoid standard chemotherapy without compromising therapeutic benefit.
Edit

CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors

PR Newswire 23 Apr 2026
NCT07334119) is a multi-center, open-label, dose-escalation trial evaluating MT-304 in adults with HER2-positive breast cancer and HER2-positive solid tumors ... HER2-positive breast cancer remains a ...
Edit

DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer

PR Newswire 09 Apr 2026
The candidate has exhibited antitumor activity in both HER2-positive and HER2-low tumor models as well as in several solid tumor indications, including patients with breast and endometrial cancers, as well as other advanced solid tumors.
Edit

Sevabertinib approved to treat adults with HER2-positive lung cancer that has spread or cannot be removed by surgery (MHRA - Medicines and Healthcare products Regulatory Agency)

Public Technologies 02 Apr 2026
Clinical trial evidence shows sevabertinib produced positive responses in 71% of previously treated patients with advanced HER2 mutations, with many positive responses lasting six months or longer.
Edit

Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive ...

Business Wire 30 Mar 2026
GH), a leading precision oncology company, today announced that real-world evidence generated from ...
Edit

ENHERTU® Approved in Japan as First Tumor Agnostic HER2 Directed Medicine for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors (Daiichi Sankyo Co Ltd)

Public Technologies 23 Mar 2026
Tokyo - (March 23, 2026) - ENHERTU®(trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with HER2 positive (HER2 [ERBB2] gene amplification or immunohistochemistry ...
Edit

ENHERTU® Now Available in Japan as First Antibody Drug Conjugate for the Second-Line Treatment of Patients with HER2 Positive Metastatic Gastric Cancer (Daiichi Sankyo Co Ltd)

Public Technologies 23 Mar 2026
Press Release ENHERTU®Now Available in Japan as First Antibody Drug Conjugate for the Second-Line Treatment of Patients with HER2 Positive Metastatic Gastric Cancer ... About HER2 Positive Gastric Cancer.
Edit

HER2 Positive Gastric Cancer Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs ...

GetNews 21 Mar 2026
Inactive Products HER2-positive Gastric Cancer Key Companies HER2-positive Gastric Cancer Key Products HER2-positive Gastric Cancer- Unmet Needs HER2-positive Gastric Cancer- Market Drivers and ...
Edit

HER2-Positive Breast Cancer Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering ...

GetNews 21 Mar 2026
Inactive Products HER2 Positive Breast Cancer Key Companies HER2 Positive Breast Cancer Key Products HER2 Positive Breast Cancer- Unmet Needs HER2 Positive Breast Cancer- Market Drivers and Barriers ...

Article Search

tools
×
×
×
×